| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | GLAUKOS CORP | 3,142,217 | 76,010,229 | 43.59% | ||
| 2 | CLOVIS ONCOLOGY INC | 407,416 | 37,465,975 | 21.49% | ||
| 3 | OCULAR THERAPEUTIX INC | 2,215,384 | 31,148,299 | 17.86% | ||
| 4 | FIVE PRIME THERAPEUTICS INC | 1,092,152 | 16,808,219 | 9.64% | ||
| 5 | ACHAOGEN INC COM | 1,281,152 | 7,379,435 | 4.23% | ||
| 6 | Biotie Therapies Corp. | 268,672 | 3,516,916 | 2.02% | ||
| 7 | CymaBay Therapeutics | 1,048,601 | 2,034,285 | 1.17% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001104659-15-073439, filed 2015.10.28).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
